Manufacturing

Dr. Reddy’s to sell API manufacturing business unit in Hyderabad, India

Dr. Reddy’s Laboratories has agreed to divest its its API manufacturing business unit located in Jeedimetla, Hyderabad, located in the Indian state of Telangana, to generics pharmaceutical firm Therapiva Private.

eTheRNA immunotherapies opens mRNA manufacturing facility in Belgium

Clinical-stage firm eTheRNA immunotherapies has opened a mRNA facility in Belgium for production of mRNA immunotherapies.

Dr. Reddy’s Laboratories sells antibiotic manufacturing site in Bristol, Tennessee

Dr. Reddy’s Laboratories has sold its antibiotic manufacturing facility and related assets in Bristol, Tennessee to Neopharma, a wholly owned subsidiary of the UAE’s largest pharmaceutical manufacturer headquartered in Abu Dhabi.

Recipharm acquires Sanofi inhalation contract manufacturing business

Recipharm has completed the purchase of Sanofi’s inhalation contract manufacturing business including a manufacturing plant situated in Holmes Chapel, UK.

Tris Pharma acquires Pfizer’s subsidiary NextWave Pharmaceuticals

Tris Pharma, a developer of technology-based therapeutic products, has acquired Pfizer’s subsidiary NextWave Pharmaceuticals for an undisclosed sum.

Symbiosis gets FDA approval for manufacturing fill/finish process

Sterile manufacturing CDMO Symbiosis Pharmaceutical Services has secured approval from the US Food and Drug Administration (FDA) for its viral vector manufacturing fill/finish process at its biologics manufacturing facility in Scotland, UK.

Lonza adds two new Ibex solutions offerings to Swiss biopark

Swiss multinational, chemicals and biotechnology firm Lonza has added two new Ibex solutions offerings to its 100,000m² biopark in Visp, Switzerland.

Grifols secures FTC’s conditional approval for Biotest US acquisition

The US Federal Trade Commission (FTC) has approved a final order which requires Grifols to sell certain assets as a condition for its acquisition of Biotest US in accordance with the federal antitrust law.

BeiGene selects GE’s KUBio facility to boost cancer drugs manufacturing capacity

GE said that global biotech company BeiGene has selected KUBio, GE Healthcare Life Sciences’ off-the-shelf biomanufacturing facility, to increase its manufacturing capacity for cancer drugs.